# Descartes-25 in Relapsed/Refractory Multiple Myeloma

> **NCT05113342** · PHASE1 · TERMINATED · sponsor: **Cartesian Therapeutics** · enrollment: 9 (actual)

## Conditions studied

- Multiple Myeloma
- Relapse Multiple Myeloma

## Interventions

- **DRUG:** Descartes-25

## Key facts

- **NCT ID:** NCT05113342
- **Lead sponsor:** Cartesian Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-25
- **Primary completion:** 2023-05-09
- **Final completion:** 2024-11-08
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Phase 1 enrollment completed. Further clinical development terminated.
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113342, "Descartes-25 in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05113342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*